Signaling Pathways in Cancer Pathogenesis and Therapy

Since the 1940s, the treatment of advanced cancer has been based on administering maximal doses of non-specifically toxic drugs in the hope that cancer cells would be killed more effectively than normal cells.  While this is occasionally successful, for most common cancers only a minority of patient...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
Άλλοι συγγραφείς: Frank, David A. (Επιμελητής έκδοσης)
Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
Γλώσσα:English
Έκδοση: New York, NY : Springer New York, 2012.
Θέματα:
Διαθέσιμο Online:Full Text via HEAL-Link
LEADER 03295nam a22004335i 4500
001 978-1-4614-1216-8
003 DE-He213
005 20151125161858.0
007 cr nn 008mamaa
008 111111s2012 xxu| s |||| 0|eng d
020 |a 9781461412168  |9 978-1-4614-1216-8 
024 7 |a 10.1007/978-1-4614-1216-8  |2 doi 
040 |d GrThAP 
050 4 |a RC261-271 
072 7 |a MJCL  |2 bicssc 
072 7 |a MED062000  |2 bisacsh 
082 0 4 |a 614.5999  |2 23 
245 1 0 |a Signaling Pathways in Cancer Pathogenesis and Therapy  |h [electronic resource] /  |c edited by David A. Frank. 
264 1 |a New York, NY :  |b Springer New York,  |c 2012. 
300 |a VIII, 148 p.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
505 0 |a Signaling Pathways in Cancer:  21st Century Approaches to Cancer Therapy -- Current And Next Generation Antimitotic Therapies In Cancer -- DNA Damage Checkpoint Signaling Pathways in Human Cancer -- Non-Receptor Tyrosine Kinases and their Roles in Cancer -- The Hedgehog Signaling Pathway in Cancer Pathogenesis and Therapy -- Wnt Signaling in Cancer Pathogenesis and Therapeutics -- STAT Signaling in the Pathogenesis and Treatment of Cancer -- Protein Therapeutics in Oncology.- Index   . 
520 |a Since the 1940s, the treatment of advanced cancer has been based on administering maximal doses of non-specifically toxic drugs in the hope that cancer cells would be killed more effectively than normal cells.  While this is occasionally successful, for most common cancers only a minority of patients experience any meaningful benefit.  Unfortunately, nearly all treated patients experience toxicities, which range from unpleasant to life threatening.  In recent years, however, our understanding of the molecular underpinnings of cancer has increased enormously.  We now have a much deeper understanding of how intracellular signaling pathways that control critical cellular functions can become subverted by the genetic alterations arising in a cancer cell.  In fact, we are now in a position to use this knowledge to design rational targeted therapeutic approaches that hold the promise of much greater efficacy with fewer side effects.  In this volume, oncologists and scientists from academia, government, and industry have come together to provide insight into strategies to modulate signaling pathways, which are currently being translated from the laboratory to the clinic.  These advances will hopefully usher in a new era in the treatment of cancer patients, and thus the goal of this volume is both to inform those interested in this field, and to inspire further contributions in this cutting edge area. 
650 0 |a Medicine. 
650 0 |a Cancer research. 
650 0 |a Pharmacology. 
650 1 4 |a Biomedicine. 
650 2 4 |a Cancer Research. 
650 2 4 |a Pharmacology/Toxicology. 
700 1 |a Frank, David A.  |e editor. 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer eBooks 
776 0 8 |i Printed edition:  |z 9781461412151 
856 4 0 |u http://dx.doi.org/10.1007/978-1-4614-1216-8  |z Full Text via HEAL-Link 
912 |a ZDB-2-SBL 
950 |a Biomedical and Life Sciences (Springer-11642)